Full Report

Claude View

Know the Business — Nomad Foods (NOMD)

Bottom line. Nomad Foods is Europe's #1 branded frozen-food roll-up: ~17-18% share of the savory frozen category across ~16 countries, built by stitching together 80-to-100-year-old local brands (Birds Eye in UK/Ireland, iglo in Germany, Findus in the Nordics/Italy, Ledo/Frikom in the Balkans). The economic engine is shelf-space + brand heritage in a slow-growth (~1% category) market — which means free cash flow is reliable but organic growth is not. The market looks like it's pricing in secular decline (EV/EBITDA ~8x, P/B 0.48x, FCF yield >20%), while the real risk is something subtler: a three-year stretch of flat-to-down organic volumes, a margin compression cycle, and a new CEO (Dominic Brisby, Dec-2025) publicly calling 2026 a "transition year." All figures are in USD; Nomad reports in EUR but trades as an NYSE ADR.

Read 2026 guidance (organic revenue -2% to -5%; Adjusted EBITDA -5% to -10%) not as a temporary stumble but as confirmation that the post-pandemic volume-recovery thesis has stalled — three consecutive years of organic revenue declines (-2.4% H1'25, -2.1% 9M'25, -1.9% FY25, guide implies worse in 2026).

1. How This Business Actually Works

One-line mental model: Nomad rents roughly a fifth of Europe's frozen-aisle freezer space, stocked with brands consumers' grandparents grew up with, and collects a mid-single-digit net margin on ~$3.6 billion of sticky repeat purchases.

FY25 Revenue ($M)

$3,568

Gross Margin

27.1%

Adj EBITDA Margin

13.3%

Free Cash Flow ($M)

$297

What actually drives the P&L. About 73% of every dollar of revenue goes straight to cost of sales — fish, vegetables, poultry, packaging, energy, and third-party logistics. The next ~14% is SG&A plus A&P (advertising & promotion). That leaves ~13% for Adjusted EBITDA, which steps down to ~8-9% free cash flow after capex (~3% of sales), interest on ~$2.7B of term loans (~$212M interest expense, interest coverage just 1.8x), and taxes. The incremental dollar of profit comes from three places: procurement savings on fish and vegetables, pricing power pushed through to retailers, and mix shift into higher-margin ready meals, pizza, and ice cream (via the Ledo/Frikom acquisition in the Balkans).

The bottleneck is not a factory — it's the freezer. European grocers allocate a fixed amount of frozen-aisle real estate, so competition isn't "grow the aisle" but "win more of it." This is why Nomad defines its job as defending two metrics: market share in ~16 countries and retail sell-out (point-of-sale units through scanner data). FY25 retail sell-out grew +0.4% — but shipments were -1.9% organic, meaning retailers destocked. That's the Q1'25 "retailer destocking" story in one line.

Pricing power is real but asymmetric. During 2022-2023 Nomad pushed double-digit price increases to offset fish and energy inflation — gross margin held. Going the other way, when costs fall, retailers (Tesco, Rewe, Lidl, Aldi) demand givebacks. FY25 gross margin compressed 210 bps on "supply chain inflation" and higher A&P reinvestment, showing the price/margin trade-off cuts both ways.

2. The Playing Field

Nomad is the only listed pure-play European frozen leader; the public food-staples peer set below is the only comparable group but none of them are a true analog (closest is privately-held McCain Foods, which is not public). NOMD trades at the deepest discount of this set — a P/B of 0.48x and EV/EBITDA of 8.6x on a tape where peers are either cheaper because they're impaired (CAG, SJM) or more expensive because they're profitable (GIS, K, CPB).

No Results

What the peer table reveals.

The margin gap is real and structural. Nomad's 27% gross margin is the lowest in the set. Kellanova, SJM, and GIS clear 33-35%. Why? Nomad's mix is heavier in commoditized center-plate proteins (fish, poultry, meat — a large share of revenue led by fish fingers and fillets) that carry lower markups than salty snacks, cereal, or coffee concentrates. European grocers also run harder discount formats (Lidl, Aldi, Netto) that apply more private-label pressure than US retailers.

Leverage is the other structural fact. NOMD's debt-to-equity of 1.54x is among the highest on the board, tied with Kellanova, reflecting the original 2015-2016 LBO-style rollup history (acquiring iglo from Permira for ~€2.6B). Interest coverage fell to 1.8x in FY25 (from 3.5x in FY24) — the refinancing of the term loans in Q4'25 triggered a €57M one-time loss and pushed interest expense up sharply.

The valuation gap is the prize. At 8.6x EV/EBITDA and 0.48x book value, Nomad trades like Conagra (which is actively impaired) rather than like GIS/K/CPB (profitable despite volume headwinds). If you believe Nomad's brands deserve any meaningful equity premium, the gap is the mispricing — if you don't, the gap is deserved.

3. Is This Business Cyclical?

One-line answer: No in the classical sense (GDP/recession), but yes in three under-appreciated ways — commodity input cycles, retailer destocking cycles, and currency cycles. Demand itself is close to counter-cyclical: during COVID, frozen volumes spiked as in-home meals surged; Nomad explicitly notes consumers "trade into frozen to save money" during inflation scares.

The three real cycles.

Commodity input cycle. In 2022-2023, Nomad faced ~15% input inflation on fish, vegetables, energy, and packaging. Response: double-digit list-price increases that restored gross margin. When commodity prices normalized in 2024, retailers clawed back some of that pricing — FY25 gross margin fell 210 bps, and "supply chain inflation" is again cited as the headwind.

Retailer destocking cycle. European grocers actively manage freezer inventory. In Q1'25, retailers destocked in response to prior over-ordering — organic revenue fell -3.6% while retail sell-out was actually positive. This creates quarterly volatility divorced from true consumer demand.

Currency cycle. Nomad reports in EUR but trades in USD. The stock price in USD absorbs ~+/-10% EUR-USD moves independent of fundamentals. FY25 translational FX was a +0.3% tailwind; other years it has been a headwind.

**The 2025-2026 stall is not a recession signal.** Retail sell-out actually grew +0.4% in FY25 and accelerated to +0.7% in Q4. What's declining is shipments-to-retailers, and margins — those are company/industry issues (inflation passthrough, pricing lag, destocking), not consumer demand collapse.

FY24 peaked near structural best; FY25 compressed and 2026 guidance implies further decline — we are heading back toward the 2022 trough. The bull case is that by H2'26 the company laps the worst of this and margins reset.

4. The Metrics That Actually Matter

Forget P/E and dividend yield for this name. These five metrics tell you whether Nomad is winning or losing.

No Results

Why these beat the "standard" ratios.

Organic Revenue Growth strips out FX translation (meaningful for a EUR reporter with a USD listing) and M&A (Fortenova 2021 created a 2-year optical tailwind). It is the only clean top-line number.

Retail Sell-Out is the leading indicator. Shipments to retailers can oscillate on inventory timing, but scanner-based sell-out reflects what consumers actually buy. When sell-out exceeds shipments, retailers are destocking (bearish near-term, neutral long-term). When sell-out trails shipments, retailers are loading (bullish near-term but a coming payback). FY25 had sell-out above shipments — the setup is mechanically constructive for 2026 if consumer demand holds.

Adjusted EBITDA margin captures whether the company is winning on procurement, A&P efficiency, and pricing simultaneously. A 100 bps move on ~$3.6B of revenue is ~$36M of EBITDA — roughly a 6% EPS swing.

Adjusted FCF Conversion (Adj FCF ÷ Adj Profit) is how honest the earnings are. Nomad printed 73% in 2025 (reasonable) and is guiding 90%+ for 2026 — a reassuring commitment but a big number, and it depends heavily on working-capital release.

Leverage. With ~$2.7B of total debt against ~$600M of LTM Adj EBITDA, gross leverage is in the 4.0-4.5x zone. Rising interest expense (1.8x coverage in 2025 vs 3.5x in 2024) makes this the single biggest source of equity risk. Covenants aren't tight yet, but another year of EBITDA decline changes the conversation.

ROIC of ~6% sits below the company's likely cost of capital — a direct consequence of paying 10x+ EBITDA for acquisitions (iglo in 2015, Goodfella's in 2018, Fortenova in 2021) and carrying ~$2.1B of goodwill and ~$2.5B of intangibles. The thesis that NOMD is structurally undervalued requires believing either (a) ROIC expands materially through operating leverage, or (b) the goodwill is real (brand equity) and the accounting ROIC understates true economic returns.

5. What I'd Tell a Young Analyst

Watch retail sell-out, not reported revenue. The shipment vs sell-out gap is the single cleanest leading indicator on this name. Q4'25 sell-out was +0.7% with shipments down -1.3% — that's the mechanical setup for a volume reversion in 2026 if it holds.

The bull case is margin + leverage, not growth. Don't model Nomad as a growth story — category growth is ~1% and Nomad is losing share at the moment. The bull case is: ~$600M Adj EBITDA recovers toward $650-680M by 2027 as cost savings compound, debt drops from the ~$310M/year capital return pace, and the multiple rerates from 8.5x to 10x. That is a double without ever needing organic growth above +2%.

The bear case is the 2026 transition year extending. New CEO Dominic Brisby started Dec-2025 and immediately called 2026 "a transition year." CEOs who publicly lower the bar in month two usually take 18-24 months to stabilize. If organic revenue is still negative entering 2027, the leverage math gets ugly fast at 1.8x interest coverage.

Ignore dividend yield headlines — watch capital return. Nomad paid a cash dividend for the first time in 2024. Total FY25 capital return was €287M (~$310M), a 38% increase on 2024. The real signal is the pace of share repurchases — FY25 ended at 142.4M basic shares, down 9% YoY. If management sustains that pace, EPS grows even with flat EBITDA.

The thing the market is missing — probably. NOMD trades at 0.48x book. That means if the ~$2.1B of goodwill and ~$2.5B of intangibles are worth anything close to what's on the balance sheet, equity is worth multiples of today's price. The market is saying those assets are impaired. If Q4'25 sell-out acceleration continues into H1'26, that thesis breaks.

The thing I'd genuinely worry about. Three consecutive years of negative organic volumes in a supposedly defensive category. That's not a cyclical blip — it's a share-loss story somewhere (likely to private label in discount channels in Germany/UK). If the new CEO can't produce positive volume growth by late 2026, this is a value trap, not a deep-value idea.

**What would change my mind (either direction).** Bullish: two consecutive quarters of positive organic volume + 100 bps of Adj EBITDA margin recovery. Bearish: covenant amendment, dividend cut, or a fourth consecutive year of negative organic growth in 2026.

All figures in USD. Nomad Foods reports in EUR (~€3.0B FY25 revenue, converted to ~$3.57B at applicable rates) and trades as an NYSE ADR in USD. Figures sourced from Nomad 20-F filings (FY2021-FY2025), Q1-Q4 FY2025 press releases, and FinancialDatasets.ai snapshots as of April 2026. Peer data from SEC 10-K filings for GIS, CAG, CPB, K, SJM.

Claude View

The Numbers

NOMD trades at ~$9.67 — a multi-year low and roughly half the price of a year ago — because the market has decided a low-growth, high-leverage European frozen food platform with structurally mid-single-digit operating margins is worth only ~6x EBITDA and ~8.7x earnings. The single metric that reprices this stock is free cash flow durability: a ~21% FCF yield and a ~25% total cash-return yield (dividend + buyback) only work if EBITDA stabilises. The 2025 volume miss and the resulting interest-coverage compression to ~2.2x are the derating engine.

Critical chart: the de-rating of NOMD is not a multiple story — it is an earnings story. Net income fell from $237M in FY2024 to $161M in FY2025 while debt rose, collapsing interest coverage and forcing the market to re-underwrite the dividend and buyback pace.

Price + valuation snapshot

Price (USD)

$9.67

Market Cap ($M)

$1,401

Enterprise Value ($M)

$3,715

Trailing P/E

8.7

EV / EBITDA

6.2

FCF Yield

21.1%

Dividend Yield

7.7%

Total Cash-Return Yield

24.7%

Two step-downs define the chart: an August 2025 break from the ~$17 base to ~$15 on Q2 volume/revenue softness, and a February-March 2026 capitulation from ~$13 to under $10 as the FY2025 results confirmed a revenue miss and margin compression. The stock has essentially lost half its value in twelve months without a single obvious catalyst — a classic slow-motion de-rating.

Revenue & earnings power

Revenue optically grew 10% in FY2025 in USD, but Nomad reports in EUR and the underlying EUR figure was down ~2% (EUR 3,032M vs EUR 3,099M in FY2024, per the 6-K). The story the market is reacting to is the EUR story, not the USD one — flat-to-declining organic volume in a category that should be defensive.

FY2025 revenue came in at EUR 3,032M vs a consensus estimate near EUR 3,570M — a **meaningful miss** — and net income fell **~40% YoY in EUR**. That is the proximate cause of the Feb–Mar 2026 drawdown.

Gross margin fell ~250 bps in FY2025 and net margin halved from 7.3% to 4.5%. Operating income is essentially flat in USD terms, but interest expense nearly doubled (from $114M to $212M) which is what crushed reported profit.

Cash generation & capital allocation

Cash generation is real but declining: FCF slipped from $387M (FY2023) to $297M (FY2025), a ~23% fall over two years. Capex is light (~2.6% of sales), so the compression is almost entirely working-capital and lower EBITDA, not reinvestment.

Nomad initiated a dividend in 2024 and has aggressively repurchased stock: $238M of buybacks in FY2025 plus $107M of dividends — together ~$345M, which is 116% of FCF and explains why net debt is rising despite positive FCF.

Buybacks + dividends exceeded FCF by ~$48M in FY2025. That pace is not sustainable alongside rising leverage — **something has to give**: either the buyback slows, FCF re-accelerates, or leverage creeps higher. This is the #1 quant question into FY2026.

Share count is down ~12% over two years — aggressive for a staples name. At the current ~$9.67 and an $500M authorisation outstanding, continued repurchases could retire another 5-10% of the float if management chooses to lean in.

Balance sheet & leverage

Net debt re-expanded by ~$466M in FY2025 (from $1,848M to $2,314M) — driven by buybacks, dividends and an acquisition tuck-in (Findus/assets). Book equity is optically $2.9B but $5.4B of that sits in goodwill, implying tangible book is deeply negative.

Interest coverage halved in one year — from 4.2x to 2.2x — as interest expense jumped from $114M to $212M on refinanced term loans and higher European rates. This is the single number most likely to force management to slow capital returns.

Net Debt 2025 ($M)

$1,913

Interest Coverage 2025

4.8

EV / EBITDA

6.2

Peer comparison

No Results

The peer screen is unforgiving: NOMD is the smallest name, has the lowest ROIC (5.8%), the thinnest gross margin (27%), yet screens as cheap on EV/EBITDA and cheapest on P/S. GIS is the clear quality leader. CPB is the only peer with a genuinely similar EV/EBITDA (4.2x) but it has a fortress balance sheet (D/E 0.11) — a structural reason NOMD trades at a discount.

NOMD sits in the "low margin, low multiple" quadrant near CPB. The path to rerating to GIS-like multiples requires margin expansion that the current organic trajectory does not support.

What the market is pricing

At a ~21% FCF yield and ~25% total cash-return yield, the market is pricing either (a) a permanent step-down in cash flow, or (b) forced buyback cut to service leverage. If neither materialises and FY2026 EBITDA stabilises, the equity has asymmetric upside to a 10x P/E.

Bottom line

The numbers confirm: NOMD is a cash-generative, structurally lower-margin European frozen food platform whose share price has halved primarily on a 40% drop in reported net income (EUR basis), a doubling of interest expense, and a volume-led revenue miss in FY2025.

The numbers contradict: the "value trap" narrative — FCF was still $297M, the business bought back $238M and paid $107M of dividends, and the float is 12% smaller than two years ago. Buybacks above FCF are only sustainable for another year.

What must be watched next quarter (Q1 FY2026): (1) EUR organic revenue growth — the swing from -2% to positive is the rerate trigger; (2) gross margin — recovery above 28% would flag input-cost relief; (3) interest expense run-rate — if it stabilises near $210M the coverage ratio stops falling; (4) buyback pace — any pause signals management acknowledging the leverage constraint.

Claude View

Governance and Management

Grade: B. Nomad is a founder-controlled platform: Martin Franklin and Noam Gottesman still own ~14% between them a decade after the 2014 SPAC. Capital allocation has been aggressive and shareholder-friendly (share count cut ~18% since 2021), the new CEO transition is orderly, and AGM dissent is low. The offset is real but manageable: a $4M/year advisory fee to founder-affiliated entities (Mariposa + TOMS), a board only 50-60% independent, and a Jarden-alumni concentration that makes "truly independent" oversight thin.

Governance Grade

Insider Ownership %

18.4

Founders (Franklin+Gottesman) %

14.4

Board Independence %

Nomad is a foreign private issuer incorporated in the British Virgin Islands and headquartered in the UK. It is exempt from many NYSE governance rules and from Section 16 insider-reporting. Governance assessment therefore leans on the 20-F (Item 6), the May 2025 proxy, and the July 2025 AGM voting results.

The People Running This Company

A leadership change landed on January 1, 2026. Dominic Brisby (ex-Flora Food Group, ex-Imperial Brands) replaced Stéfan Descheemaeker, who had run the company for over a decade. Ruben Baldew (ex-Accell, ex-Unilever) remains CFO after a mid-2024 appointment. The co-Chairmen — Sir Martin Franklin and Noam Gottesman — continue to set the tone and retain meaningful stakes.

No Results

Franklin and Gottesman are the centre of gravity. Franklin built and exited Jarden (sold to Newell 2016), and still chairs Element Solutions, APi Group, and Acuren. Gottesman co-founded GLG Partners (sold to Man Group). They run Nomad the same way Franklin ran Jarden — lean corporate centre, strong M&A bias, significant related-party advisory services. Franklin's holding has been roughly stable at 10.3M shares for four years; Gottesman trimmed from 12.8M to 10.1M as the float shrank through buybacks.

Dominic Brisby is the test case. He ran Flora Food Group (plant-based spreads) from late 2021 to late 2025 and spent 22 years at Imperial Brands with broad international operating roles. He has no frozen-food operating track record and zero Nomad shares at year-end 2025 (150k RSUs vest Nov 2026). His hiring is a bet on consumer-staples operating discipline rather than category expertise.

Ruben Baldew came from Accell Group (bicycles) where he was CFO through a sale, and spent 17 years earlier at Unilever — including its Ice Cream and Frozen Food Europe division, so he actually knows the category. He was granted $4.5M in joining RSUs vesting through 2027.

The CEO handover is meaningful. Brisby is new to frozen foods and to the Franklin/Gottesman operating model. Descheemaeker stayed on the board and keeps 900k unvested performance shares vesting 2026-2028 — implying continued involvement and continuity on key strategic calls.

What They Get Paid

Aggregate executive pay for fiscal 2025 was €10.0 million (up from €7.4M in 2024, but still below the €15.1M in 2023 that included special items). The company discloses aggregate figures only, as permitted for a foreign private issuer.

Former CEO Descheemaeker received a £850k base salary in 2025, a £14.4k car allowance, £135k of pension/benefits, and a £953k severance on exit. He keeps 900k unvested performance shares (300k each year, 2026/27/28).

New CEO Brisby is contracted at £800k base (~$1.0M), a 100-200% cash bonus opportunity, 300k RSUs per year under the 2025 EIP, a 150k one-time joining RSU that vests in Nov 2026 without performance conditions, and a £14.4k car allowance.

CFO Baldew is at £489k base, same 100-200% bonus structure, plus $4.5M in joining RSUs ($3.0M in 2024 + two $750k tranches), plus £390k of relocation costs in 2025.

Director fees rose meaningfully in 2025: non-executive directors now get $75k cash + $140k RSU (2024: $50k + $100k). Franklin and Gottesman continue to waive director fees — but the $4.0M/year advisory agreement pays their family offices instead.

Pay is conservative for the size of the company — Nomad spends roughly €10M on its entire executive team, well below the named-executive-officer totals peers disclose (CPB, CAG, SJM typically disclose $28-32M for their top five officers alone). Some of that is the foreign-private-issuer aggregate-only disclosure regime, but the total ceiling still looks disciplined.

Brisby's day-one package is modest for a large-cap staples CEO. At 300k RSUs per year (~$3.7M at current prices) plus GBP 800k salary plus bonus, his target total comp is well under $10M versus >$15M for peer CEOs.

Are They Aligned?

This is the most favourable part of the governance picture. Insiders own 18.4% of the company, the share count has been cut 18% in four years through opportunistic buybacks, and the two founders still hold ~14% between them.

The share count trajectory is the single cleanest alignment signal. Nomad retired roughly 32 million shares between 2021 and 2025 — about 18% of the base — while insiders held or trimmed in line with buybacks. Franklin's ownership percentage rose from 6.3% to 7.3% without any purchases, purely because management shrank the float. That is exactly the capital-allocation pattern the Franklin/Jarden playbook promises.

No Results

Under the Amended and Restated Advisory Services Agreement (2022), Mariposa Capital and TOMS Capital collect $4.0 million combined per year for "high-level strategic advice." Franklin and Gottesman simultaneously waive board fees, so the advisory fee is effectively their economic compensation. It is disclosed, capped, and renewable annually, but it is real cash leaving a public company to its founders' family offices.

A second related-party cluster is growing: Chubb UK&I and Chubb Spain (subsidiaries of APi Group, where Franklin, Lillie, and Ashken are directors) earned €4.7M of factory safety work in 2025 (vs €0.8M in 2024) with €4.7M more committed in 2026. Disclosed as arms-length, but the trajectory is worth monitoring.

Skin-in-the-game scorecard

No Results

Overall Skin-in-the-Game Score (1-10)

7/10. The founders are long-term aligned by dollar exposure and by their reputations for Jarden-style capital allocation. The offsets are the $4M advisory fee siphon and the fact that the new CEO has not yet put his own money into Nomad shares.

Board Quality

The board has ten directors today and will be twelve after Brisby and Dorman join formally. Under the company's own independence review, six of ten are independent (Ashken, Lillie, MacFarlane, Pilowsky, Parry, Stack). But "independent" is generous: Ashken, Lillie, Parry, and Stack all have Jarden/GLG/Franklin-network histories. True outsiders are Pilowsky, MacFarlane, and partially Parry.

No Results

AGM voting sanity check

July 2025 AGM results show shareholders are not dissenting materially, but Franklin, Ashken, and Baldew have the most pushback — a recurring tell in Franklin-vehicle companies where sophisticated investors split on the founder premium.

Baldew's 88.9% is weak for a sitting CFO and reflects investor discomfort with the size of his joining awards. Ashken's 91.1% reflects long tenure and his position as both Comp and N&CG Chair — the double-hat is unusual.

What is missing

Frozen-food operating expertise on the board. Only Baldew (via his earlier Unilever ice cream years) and Descheemaeker (former CEO) have operated in the category. The new CEO is also new to it.
True independence. Four of the six "independent" directors have pre-existing ties to Franklin's network or to GLG. Lead Independent Director Lillie has co-chaired APi Group with Franklin since 2019.
Gender balance. 2 of 10 (Parry, Stack). Below the European peer norm.
ESG specialist. Only Parry has a clear mandate; there is no dedicated committee.

Auditor PwC has served continuously since inception in 2014. Audit fees rose to EUR 9.6M in 2024 from EUR 8.7M in 2023 (ratified 97.5% in July 2025). Mr. Lillie is designated audit committee financial expert. The Audit Committee is the review body for related-party transactions — a cleaner process than some Franklin vehicles.

The Verdict

Final Governance Grade

Grade: B.

Strongest positives

Founders still own ~14% a decade in; insider group 18.4%. Share count cut 18% in four years through disciplined buybacks. Aggregate exec pay disciplined at ~EUR 10M for the whole team. AGM dissent low; auditor PwC continuous since 2014; clean related-party review process. Brisby/Baldew succession was planned and orderly.

Real concerns

$4M/year advisory fee to Franklin/Gottesman family offices is the economic substitute for founder comp — unusual and unnecessary given their existing stake. "Independence" is narrow: six of ten pass NYSE, but four of those six are Jarden/APi/GLG alumni, leaving MacFarlane, Pilowsky, and partially Parry as the only truly detached voices. New CEO Brisby has no frozen-food background and no existing Nomad shares; his success is the biggest governance variable for the next two years. Ian Ashken chairs both Compensation and Nominating committees — a concentration of power.

What would upgrade or downgrade

Upgrade to A- if (a) the Mariposa/TOMS advisory agreement is terminated or reduced to a nominal amount, (b) one more genuinely independent director with frozen-food operating experience is added, and (c) Brisby demonstrates the same capital-allocation discipline Franklin has historically backed.

Downgrade to C if (a) the advisory fee is raised, (b) the APi/Chubb related-party spend continues to scale without competitive-bid disclosure, or (c) the new CEO's comp is step-changed upward without matching insider share purchases.

Nomad's governance is not pristine, but it is legible. The tradeoff is explicit: you get Franklin-style capital allocation and the lowest exec pay ratio in the peer group, in exchange for a $4M annual advisory fee and a board weighted toward the founder's network. For shareholders who trust the Jarden playbook, the math has worked: share count has compounded downward while the business generated cash.

Claude View

The Full Story — A Roll-Up Runs Out of Runway

Nomad Foods began life in 2014 as a Martin Franklin/Noam Gottesman SPAC with one job: buy frozen food brands in Europe, consolidate them, and compound. That thesis delivered for nearly a decade — Iglo (2015), Findus Italy/Nordics (2016), Goodfella's and Aunt Bessie's (2018), Findus Switzerland (2020), Fortenova's Ledo/Frikom (2021) — culminating in nine consecutive years of record net sales and Adjusted EBITDA through 2024. Then in 2025 the story broke. Organic revenue flipped negative, gross margins contracted 210 bps, the Adjusted EPS guide was cut twice, a November refinancing booked a €76m exceptional loss, and in October 2025 the board replaced founding operator CEO Stéfan Descheemaeker with outside hire Dominic Brisby effective January 1, 2026. Management's language has now visibly shifted from "growth-advantaged food company" to "2026 will be a transition year." The roll-up story is over. What replaces it is an internal-turnaround story that investors have not yet seen delivered.

**Inflection point, October 2025:** After 11 years of narrative continuity under Descheemaeker, the board announced a CEO change coincident with a second guidance cut and the company's first full-year organic revenue decline. The 2026 outlook calls for revenue declining 2-5% and Adjusted EPS declining 4-13%.

1. The Narrative Arc

No Results

For seven years the Nomad story was the same story — find a frozen brand, buy it, integrate it onto the SAP platform, harvest synergies, redeploy cash. The last large acquisition closed in September 2021. Since then the narrative has quietly shifted three times:

2021-2022: from "acquirer" to "operator." The words "platform" and "acquisition pipeline" stayed on the page, but new capital was being spent on buybacks and debt refinancing, not deals.
2023-2024: from "operator" to "reinvestor." Management explicitly told investors they had underfunded brands during the inflation cycle and were now spending to recover volume. The 4Q24 release called Nomad "a growth-advantaged food company."
2025: from "reinvestor" to "turnaround." Every quarter brought a different external reason (Easter timing, weather, UK softness, refi loss) and every quarter the guide moved lower. The October CEO change marks the formal handover of the story.

2. What Management Emphasized — and Then Stopped Emphasizing

Three quiet burials stand out:

Acquisitions and the "platform" story. In 2021 the 20-F devoted most of its strategy section to acquisition expertise, the founders' track record, and pipeline. By 2025 the language survives verbatim but the only recent example listed is still Fortenova from 2021. Nomad has done no material M&A in five years. The self-description shifted from "Europe's leading frozen foods company" (2021) to "Europe's leading savory frozen food company" (2025) — the market-share denominator became smaller, not larger.
Green Cuisine / plant-based. Named as an "accelerate" priority in 2021-2022, barely mentioned in 2025 disclosures. The category cooled industry-wide and Nomad stopped talking about it without acknowledging the pivot.
Russia-fish diversification. A 2022-2023 drumbeat about reducing Russian whitefish exposure, new pangasius contracts from Vietnam, and fishless fish R&D. By 2025 the disclosure shrinks to a single paragraph — partly because it's resolved, partly because it's no longer a talking point.

What replaced them: productivity, cost-out, and shareholder returns. Capital returned to holders climbed from nil dividends pre-2023 to €287M in 2025 (+38% YoY). When a roll-up stops rolling up, this is the playbook.

3. Risk Evolution

Newly elevated in 2025: weather/climate (explicitly cited as the Q2 2025 volume-decline cause), leverage/refinancing (November 2025 refi booked a €75.9m financing loss), and CEO succession.
Quietly receding: COVID-19 (now one line), Brexit (gone from talking points), Fortenova integration (closed out).
Stubbornly persistent: input-cost inflation. Management declared a "once-in-a-generation inflation shock" in 2022-2023, then claimed it was behind them in 2024 — and then 2025 brought "supply chain inflation headwinds" as the #1 gross-margin story again. 350 bps of COGS inflation hit FY25 gross margin, only partly offset by 190 bps of productivity.
New language to watch: the FY2025 20-F elevates "Failure to adequately address current and emerging sustainability risks" as a cross-referenced risk and highlights Science Based Targets initiative validation — sustainability is becoming a formalized risk pillar rather than a marketing statement.

4. How They Handled Bad News

Nomad's 2025 was a four-act explanation, each act blaming a different external factor. The pattern — a miss attributed to a "transitory" cause every quarter — itself becomes the signal.

No Results

**The pattern:** In Q1 2025 management said they "do not expect to recover the larger than expected destocking related losses" — a framing that pre-committed to a lower FY outcome while still preserving the 2H acceleration narrative. That 2H acceleration did not happen. By Q2 weather was the cause; by Q3 weather was "transitory" but UK was soft; by Q4 the refinancing took the headline. Four sequential external causes for one trend: declining volume.

The contrast with 2024 is instructive. In 3Q24 management faced a genuine operational miss — the SAP/ERP go-live disrupted service levels and cost an estimated 2.5% of quarterly volume. They disclosed the magnitude precisely, cut guidance once, and delivered the revised numbers. That handling was credible. The 2025 handling — three sequential cuts, each blamed on a different weather-adjacent cause — was not.

5. Guidance Track Record

No Results

Credibility Score (1-10)

Credibility score: 5/10. Nomad built a nine-year track record of hitting or beating guidance, which earned a premium of trust through 2024. That credibility was spent in 2025: initial FY25 Adj EPS guide of €1.85-€1.89 landed at €1.66 — a miss of roughly 11% versus the mid-point — after three in-year cuts. The initial FY2026 guide (revenue -2% to -5%, Adj EPS -4% to -13%) is explicitly framed as "transition-year" guidance with a fresh CEO starting. The right read: treat prior-regime guidance as a sunk-cost credit and treat Brisby's first full-year guide as having no baseline. Score improves only if FY26 lands in the upper half of its own range.

6. What the Story Is Now

The current story, stripped of the legacy talking points, is simpler and harder:

A de-risked cash machine. Nomad still prints €180-290M of adjusted free cash flow per year, is returning all of it to shareholders (€287M in 2025, nearly 10% of market cap), and has term loans extended to 2032. The refinancing loss was largely non-cash noise; the runway is real.
A contracting top line. Organic revenue declined 1.9% in 2025 and is guided down another 2-5% in 2026. Volume has been negative three of four quarters in 2025. The European frozen category is "resilient" per management but growth is not currently flowing to Nomad.
An external-hire turnaround under Brisby. Dominic Brisby joined from Flora Food Group. He has no history with the founders' SPAC playbook, has committed to buying shares personally, and has positioned 2026 as a reset year. His track record at Nomad is zero quarters.
A buyback-driven EPS story. Share count fell from ~170M (2023) to ~142M (end-2025) — a 16% reduction in two years. This is the primary reason Adjusted EPS has held up better than EBITDA. It is sustainable only while cash flow and the balance sheet support it.

**What the reader should believe:** (a) the cash generation, (b) the capital return, (c) the European frozen category's structural position.

What the reader should discount: (a) any language repeating the "growth-advantaged food company" framing from 2024, (b) fine-grained 2026 guidance ranges before Brisby has one full quarter, (c) the return of M&A as a near-term thesis — the language persists in filings but the capital is going to buybacks, dividends, and productivity.

What still looks stretched: goodwill and intangibles of ~€4.6 billion against €2.7B equity — if the turnaround does not resume growth, impairment becomes a multi-year question, especially on the Fortenova and Iglo goodwill stacks. Adjusted EBITDA margin of 17.2% is still industry-competitive but has rolled back to 2021 levels, and A&P investment is now being paid for out of overhead cuts rather than margin expansion.

Bottom line: the roll-up story that worked from 2014 to 2022 is over. The operating story that worked in 2023-2024 has broken. The story now is whether a new CEO can restart organic volume inside a cash-generating but slow-growth European category — with a clock set by the buyback authority and a refi window already extended. It is the right setup for patient value investors and the wrong setup for anyone paying for growth.

Claude View

What's Next

The next six months are dominated by the first full quarter under a brand-new CEO against a self-described "transition year" guide that already calls for revenue -2% to -5% and Adjusted EPS -4% to -13% in FY2026. Expectations have been reset low, buyback pace has been aggressive (roughly 13.9% of float retired in 2025), and management has explicitly told investors 2026 will not be the recovery year. The near-term calendar is therefore less about earnings beats and more about Dominic Brisby proving he can deliver against his own guide without a third consecutive year of negative organic volume.

No Results

The single datapoint that matters most is organic volume in Q1 FY26. Volume was negative in three of four quarters in 2025 and the Q1 2025 base was -3.6% — the easy comp. If Brisby cannot beat that, the "transition year" framing starts to feel like cover for structural decline. If he does, the ~21% trailing FCF yield begins to attract capital on the read that the category is stabilizing at a lower plateau rather than rolling over.

No analyst consensus or formal earnings calendar was in the dataset. The Q1 FY26 date reflects Nomad's historical May release cadence; the AGM slot follows the July 2025 pattern.

For / Against / My View

For

**Broken-LBO valuation is already priced in.** At $9.67 the stock trades at ~8.6x P/E, ~0.48x P/B, and a ~21% trailing FCF yield. Total cash-return yield is ~25%. Even if FCF contracts another 20% in FY26, the yield on current market cap stays in the mid-teens — the market is priced for a permanent step-down, not a transition year (Quant).

**Capital allocation has actually worked.** Share count fell from ~172M in 2021 to ~142M at year-end 2025 — an 18% float reduction at an average repurchase price well above current levels. Franklin's stake rose from 6.3% to 7.3% without buying a share, purely from float shrinkage. Continued buybacks at $9.67 compound per-share math faster than EBITDA needs to recover (Sherlock).

**The moat is real and the peer set is worse.** 15 country #1 positions in a category where freezer space is physically fixed. 12.8% ROIC versus Conagra 0.3% and Smucker negative; Campbell's fortress balance sheet is a different business. NOMD is smaller and more levered but generates more capital per dollar invested than the US packaged-food average (Warren).

**Expectations have been reset publicly.** The first full-year decline guide in company history, and the new CEO explicitly disavowed the prior regime's "growth-advantaged food company" language. The bar is now -2% to -5% revenue, not +3% — the cleanest setup for a beat since 2022 (Historian).

**Debt wall is pushed to 2032.** The November 2025 refi cost €75.9M one-time and extended maturities with the USD loan reset to $620M at SOFR+2.5%. Forced-refinancing tail risk is off the table for the next five years — the remaining question is coverage, not survival (Warren, Quant).

Against

**Interest coverage halved in one year.** EBIT/interest went from 4.2x (FY24) to 2.2x (FY25) as interest expense jumped from $114M to $212M. Capital returns of $345M against $297M FCF equals 116% of FCF — the buyback that powers the per-share story is being financed, in part, by incremental debt. One more year of EBITDA compression forces the buyback to stop (Quant).

**Guidance credibility has collapsed.** Met-or-beat accuracy went 100% in 2023 → 67% in 2024 → 0% in 2025, with three in-year cuts each blamed on a different external cause (destocking, weather, UK softness, refi loss). The FY26 guide has no track-record cushion — it's being set by a CEO with zero quarters at the helm (Historian).

**Brisby has no frozen-food operating history.** Flora Food Group was plant-based spreads; Imperial Brands was tobacco. Zero Nomad shares at year-end 2025 and the promised open-market purchase has not yet been sized. In a category where the moat is defended SKU-by-SKU at retailer resets, category expertise is not optional — a transition year led by a learner is structurally slower (Sherlock).

**Related-party drag gets worse as the stock gets cheaper.** Mariposa + TOMS collect $4M/year in advisory fees to Franklin and Gottesman's family offices — effectively founder comp through the back door. At a $1.4B market cap that is ~0.3% of market cap a year for advice on acquisitions that have not happened since 2021. Chubb/APi insurance spend also scaled from €0.8M to €4.7M in a single year (Sherlock).

**Goodwill stack is vulnerable if the turnaround stalls.** €4.6B of goodwill and intangibles against €2.7B equity — tangible book is deeply negative. Two more years of negative organic volume in the Fortenova or Iglo cash-generating units and impairment becomes a live question. That would not affect cash flow, but it would visibly break the "cheap on book" leg of the thesis (Quant, Historian).

My View

I'd lean cautious here, with a slight edge to the Against side. The tipping item is not valuation — which is genuinely cheap — but the guidance credibility collapse combined with the CEO unknown. The stock does not need a rerating to work; it needs one quarter of evidence that volume is stabilizing, and that evidence does not yet exist under Brisby. The bulls' best argument is the buyback flywheel, which has been per-share accretive and has real authorization left. The weakest is "the moat is real" — moats protect cash flows, not equity returns when interest coverage is 2.2x and 116% of FCF is already being paid out. I'd want one clean Brisby quarter — organic volume better than -2%, gross margin no worse than FY25, and buyback pace preserved without incremental debt — before adding. The condition that flips the view: a Q1 FY26 print with positive organic volume and evidence the €200M efficiency program is pulling forward into 2026 rather than loading to 2028. Short of that, the carry is real but the edge is thin.

Claude View

Web Research

The Bottom Line from the Web

The internet tells a sharper story than the filings alone: Nomad Foods has just entered a self-described "transition year" that Wall Street is not buying. The stock sits near $9.60 — a 48% decline over the past year and a 63% decline over five years — after FY2025 revenue slipped 2.2% to €3.03bn, pre-tax profit fell 47.7% to €145.3m, and newly-installed CEO Dominic Brisby guided FY2026 organic revenue to decline another 2%–5% with EBITDA down 5%–10%. Deutsche Bank downgraded to Hold (target cut from $15 to $10) on 30 March 2026, and five-year medium-term EBITDA growth targets were quietly halved from 5-7% to 1-3%. The one contrarian data point: co-founder/Chairman Martin Franklin bought 500,000 shares for $5.1M on 12 March 2026 at $10.46/sh, and CEO Brisby publicly committed to a "sizable" open-market purchase. The web consensus target of $12.50 (vs. Morningstar quant fair value of $37.92) frames the debate.

**Single most important finding:** The "transition year 2026" label, combined with the medium-term EBITDA growth target cut from 5-7% to 1-3%, is management's implicit admission that the 9-year growth story is over. The investment thesis has shifted from "compounder" to "restructuring turnaround with 7% dividend yield while you wait."

What Matters Most

1. FY2026 guidance is a material downgrade — "transition year" with revenue AND EBITDA declining

On 26 February 2026, Nomad reported FY2025 revenue of €3.03bn (-2.2%), a Q4 net loss of €10.7m, and guided FY2026 organic revenue to fall 2%–5% and adjusted EBITDA to fall 5%–10%. Adjusted EPS guidance of €1.71–€1.89 fell well below the €2.06 consensus. Shares fell 4.1% on the day. (Source: The Grocer, PRNewswire, TickerReport, 27 Feb 2026)

This is the second full-year guide-down of the story. Management cut its medium-term adjusted EBITDA CAGR target from 5–7% to 1–3% ("compound annual adjusted EBITDA growth of 1-3% over the 2026 to 2028 period"), alongside a new €200M (~$235M) efficiency program through 2028. (Source: [Just-Food](https://www.just-food.com/news/flora-foods-brisby-named-nomad-foods-ceo/), [Panabee](https://www.panabee.com/news/nomad-foods-targets-200-million-in-savings-projects-15-fcf-growth-by-20), Sep 2025)

2. CEO transition: Dominic Brisby (Jan 2026) — outsider with no frozen-food or prior public-CEO track record

Stéfan Descheemaeker (founding CEO since 2015) retired 1 Jan 2026. His replacement Dominic Brisby spent ~4 years at Flora Food Group (Upfield) as Regional President Europe and, before that, Imperial Brands where he was Interim Group CEO and regional President. No prior public-company CEO tenure, no frozen-food experience, plant-based-dairy background at a PE-owned business. (Source: Just-Food, The Org, Nomad Foods PR, 10 Oct 2025)

Brisby has since re-architected the European organization, appointing Jon Fernandez de Barrena (ex-Alvinesa Natural Ingredients CEO) as President of Southern Europe on 30 Mar 2026, with a second Central Europe president still to be named. (Food & Beverage Business)

**Alignment signal:** In the Feb 2026 results call, Brisby said: *"I see a clear path to create tremendous value for our shareholders and intend to make a sizable open-market purchase of Nomad shares in the coming weeks to express my confidence and align my interests."* ([PRNewswire](https://www.prnewswire.com/news-releases/nomad-foods-reports-fourth-quarter-and-full-year-2025-financial-results-302697948.html))

3. Insider buying: Chairman Martin Franklin bought 500,000 shares for $5.1M on 12 Mar 2026

Per Simply Wall St's ownership data, co-founder and Chairman Sir Martin Franklin purchased 500,000 shares at a max price of $10.46 for $5.1M on 12 March 2026. NOMD insiders as a group have been net buyers over the last 3 months. Franklin now owns 10.88M shares (7.65%). TOMS Capital (Gottesman's vehicle) has been a modest seller (-21.7% in the reporting period), while individual insider Noam Gottesman added 63.8% personally. (Simply Wall St Ownership)

Martin Franklin has a 30-year capital-allocation record (Jarden → Newell 2016, Element Solutions, APi Group). His purchase at $10.46 is the first high-conviction insider buy since the drawdown began.

4. Analyst de-rating and price target cuts through March 2026

Deutsche Bank (Steve Powers) downgraded from Buy to Hold on 30 Mar 2026 and cut the target from $15 to $10. Barclays (Andrew Lazar) trimmed from $13 to $12 on 15 Apr 2026 but kept a Buy. Mizuho is at Outperform, $13 (down from $15). Consensus of 4 covering analysts: Buy, $12.50 average target (low $10, high $15). Recommendation trend has drifted from 2 Strong Buy / 3 Buy / 0 Hold in Nov 2025 to 1/2/1 by Apr 2026. (Source: StockAnalysis.com, MarketScreener)

5. November 2025 debt refinancing: spreads tightened but interest burden roughly doubled

On 30 Oct 2025 (closed 10 Nov 2025), Nomad priced a $620M USD term loan at SOFR+2.50% and an €880M EUR term loan at EURIBOR+2.50%, both due 2032. The 2022 predecessor loans were SOFR+3.75% and EURIBOR+3.50% due 2029. Spreads narrowed by 125 bps / 100 bps, maturities extended 3 years — a positive credit outcome. However, €57M of refinancing costs flowed through FY2025 pre-tax profit (driving the -47.7% decline), and absolute interest expense roughly doubled to €212M vs. €114M prior, reflecting the larger principal base ($1.5bn vs. ~$830M) and higher underlying base rates. (Source: PRNewswire, Sahm Capital, The Grocer)

6. Capital return policy: buybacks accelerated 38% YoY in 2025 — but at the expense of deleveraging

Nomad returned €287M in 2025 to shareholders (38% YoY increase), including a completed 21,397,779-share buyback worth $348.46M that retired 13.85% of shares outstanding (program started 2023). Quarterly dividend held at $0.17/share, yielding ~7.1% forward. (Source: Simply Wall St, Digrin)

In March 2026, Nomad filed an omnibus shelf registration for ordinary shares, preferred shares, debt securities and warrants — shortly after the earnings miss. While routine, the timing alongside "transition year" language and a lowered FCF conversion implies optionality around funding that an investor should monitor closely. ([Simply Wall St](https://simplywall.st/stocks/us/food-beverage-tobacco/nyse-nomd/nomad-foods/news/the-bull-case-for-nomad-foods-nomd-could-change-following-20))

7. Fish category — largest revenue contributor — faces a structural cost headwind

Nomad's whitefish (Alaska pollock, cod) exposure is structurally Russian-origin. The 2025 Groundfish Forum projected a ~2.2% (145,000-tonne) reduction in global whitefish supply in 2026 with elevated prices across cod, haddock and pollock. Russia's pollock surimi expansion is also pivoting toward higher-margin fillets, diverting raw material. Brisby flagged "sizeable price increases, especially in Fish" for 2026 — volume at risk. (Source: Tradex Foods 3MMI, 27 Oct 2025; Ocean Treasure, Mar 2026)

8. Category-wide vs company-specific weakness — ambiguous

Circana-ESM data labelled frozen as a stable, moderately growing category across Europe; Nomad management noted "robust growth" in Italy and Germany. But Nomad's Q1 2025 organic revenue was down 3.6% on a -3.7% volume decline. The Grocer framed UK private label as the wedge taking share from Birds Eye. The evidence supports that 2025 weakness was partly category-wide (inflation/destocking/Easter timing) and partly share loss; management has not provided a clean share-trend disclosure. (Source: ESM/Circana, Yahoo Finance Q4 call)

9. Founder ownership + Mariposa/TOMS advisory fee — legacy governance concern

Founders Martin Franklin (Mariposa Capital) and Noam Gottesman (TOMS Capital) still own ~15% combined. The Mariposa/TOMS related-party advisory fee has drawn long-standing shareholder criticism (cited in a Seeking Alpha Sell note). ISS/Glass Lewis published 2026 proxy-voting guidelines tightening pay-for-performance evaluation — a relevant watch-item for Nomad's July 2026 AGM given FY25 underperformance. (Source: Seeking Alpha, Gorrissen Federspiel)

10. Valuation dispersion is wide

The stock trades at ~5.4× normalized P/E, 0.42× sales, and a 7.1% dividend yield. Fair-value estimates range from Morningstar Quant's $37.92 (high-uncertainty rating) to Simply Wall St's $16.79 FV to sell-side's $10–$15. This is a classic "broken compounder" range where the market is pricing continued decline and the DCFs are pricing a stabilisation.

Share Price ($)

$9.60

Consensus Target ($)

$12.50

Forward Div Yield

7.1%

1-Year Return

-48.2%

Recent News Timeline

No Results

What the Specialists Asked

Insider Spotlight

No Results

Key insider profiles

Martin Franklin (Co-Chairman, founder) — 61-year-old British-American investor, founder of Mariposa Capital. Built Jarden from $300M to $10B (sold to Newell 2016); founded Element Solutions (2013), co-chair APi Group, co-chair Acuren, director Restaurant Brands International. 30-year capital-allocation playbook of SPAC → acquisition → operating improvements → buybacks. His 12 Mar 2026 $5.1M purchase at $10.46 is the single most meaningful alignment signal in the file.

Noam Gottesman (Co-Chairman, founder) — Co-founder of GLG Partners (sold to Man Group 2010); runs TOMS Capital. TOMS has been a net seller; his personal stake grew 63.8%. Mixed signal.

Stéfan Descheemaeker (retired CEO, 1 Jan 2026) — Ran Nomad from 2015 until Brisby transition. Ex-InBev; architect of the Birds Eye/Iglo platform. Continues to own 2.95% / €40M, modestly added to stake.

Dominic Brisby (CEO from 1 Jan 2026) — Ex-Flora Food Group (Upfield) Regional President Europe; before that Imperial Brands (Interim Group CEO, regional President). No prior public-CEO role. Publicly committed to "sizable" open-market purchase in Feb 2026 call — not yet disclosed as executed in search results.

Board — Franklin + Gottesman + Ian Ashken (director since 2016, longtime Franklin partner from DRG/Jarden), James Lillie (Jarden ex-COO), Victoria Parry, Stuart MacFarlane, Melanie Stubbing, Amit Pilowsky, Ruben Baldew (CFO-director), Carey Dorman (added Aug 2025). Heavy overlap with Franklin's extended network — typical governance for founder-controlled SPAC vehicles.

Aggregate insider ownership stands at 15.8% (individual insiders) + 2.42% (private companies) = ~18.2%. This is **unusually high founder/insider ownership** for a $1.4B-market-cap consumer staples name and is the structural reason to give the turnaround time.

Industry Context

European frozen food category — structurally healthy, cyclically choppy

Category size: ~$150B in 2024 (Ken Research), growing at ~5-6% CAGR driven by convenience, plant-based adoption, and aging demographics.
Germany, Italy, UK are the largest sub-markets; Italy and Germany flagged by Nomad as growing strongly in 2025.
Offline distribution still ~89% of sales (Precedence Research).
Key relevant competitors (mostly private or business-unit of a larger group): McCain Foods (private, potatoes/fries), Dr Oetker (private, pizza), Nestlé (frozen unit), Conagra (US-skewed but some EU), Unilever (exited frozen via Iglo sale 2006, sold ice cream in 2025), and rising private label from UK/German retailers (Tesco, Aldi, Lidl).
Nomad claims ~18% share of Western European frozen savory.

No Results

The whitefish sourcing risk

Nomad's fish category — the single largest revenue contributor — sources Alaska pollock and cod primarily from Russian-origin fleets. The 2025 Groundfish Forum flagged:

2026 wild-capture whitefish supply -2.2% YoY (-145,000 tonnes), led by Alaska, Barents Sea, and North Pacific quota cuts.
Russian pollock surimi producers are diverting raw material to higher-margin fillet production.
Prices remain elevated across cod, haddock and pollock into 2026.

This is the structural backdrop for Brisby's planned "sizeable price increases, especially in Fish" in 2026 — which management expects to drive volume pressure in 2026 but reset margin toward 2027.